Stock listing
LS Exchange:A423J5 Harvard Bioscience, Inc. Aktie
German listing (LS Exchange) of Harvard Bioscience, Inc. · home listing NASDAQ:HBIO
Follow Harvard Bioscience, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:HBIO
$8.66 USD -0.34 (-3.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:HBIO
- Day range
- $8.53 – $9.00 USDNov 20, 2026
- Volume
- 22,661 sharesNov 20, 2026
- Market cap
- $39.60M USDAt the close on Nov 20, 2026 · price × 4.57M shares outstanding
- 52-week range
- $4.00 – $10.20 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $186,399 USDMedian day 16,561 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:HBIO · Home | $8.66 USD | -0.34 (-3.8%) | 22,661 | $8.58 | $9.00 | $8.53 | $9.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:HBIO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $8.66 | -0.34 | -3.8% | $8.58 | $9.00 | $8.53 | 22,661 | |
| $9.00 | -0.08 | -0.9% | $8.91 | $9.169 | $8.91 | 18,914 | |
| $9.08 | +0.17 | +1.9% | $9.00 | $9.58 | $8.825 | 28,439 | |
| $8.91 | -0.48 | -5.1% | $9.39 | $9.55 | $8.91 | 21,638 | |
| $9.39 | +0.175 | +1.9% | $9.50 | $9.67 | $9.365 | 18,784 | |
| $9.215 | -0.465 | -4.8% | $9.83 | $9.97 | $9.21 | 15,565 | |
| $9.68 | +0.42 | +4.5% | $9.46 | $10.20 | $9.30 | 105,421 | |
| $9.26 | +0.17 | +1.9% | $9.02 | $9.60 | $8.208 | 88,184 | |
| $9.09 | +0.73 | +8.7% | $8.44 | $9.32 | $8.35 | 46,845 | |
| $8.36 | -0.10 | -1.2% | $8.35 | $8.45 | $8.11 | 8,521 | |
| $8.46 | -0.15 | -1.7% | $8.68 | $8.68 | $8.21 | 74,071 | |
| $8.61 | -0.06 | -0.7% | $8.85 | $8.85 | $8.57 | 10,309 | |
| $8.67 | +0.07 | +0.8% | $8.60 | $8.82 | $8.60 | 9,431 | |
| $8.60 | -0.30 | -3.4% | $9.00 | $9.10 | $8.57 | 28,611 | |
| $8.90 | +0.10 | +1.1% | $8.80 | $8.92 | $8.71 | 23,168 | |
| $8.80 | +0.38 | +4.5% | $8.49 | $9.00 | $8.49 | 49,996 | |
| $8.42 | +0.07 | +0.8% | $8.35 | $8.48 | $8.337 | 7,985 | |
| $8.35 | +0.03 | +0.4% | $8.30 | $8.549 | $8.30 | 6,047 | |
| $8.32 | +0.09 | +1.1% | $8.17 | $8.40 | $8.17 | 24,337 | |
| $8.23 | -0.11 | -1.3% | $8.13 | $8.40 | $8.10 | 26,991 | |
| $8.34 | -0.15 | -1.8% | $8.38 | $8.45 | $8.33 | 4,432 | |
| $8.49 | +0.15 | +1.8% | $8.275 | $8.49 | $8.15 | 11,429 | |
| $8.34 | +0.25 | +3.1% | $7.90 | $8.38 | $7.90 | 23,423 | |
| $8.09 | 0.00 | 0.0% | $8.07 | $8.115 | $7.91 | 12,593 | |
| $8.09 | -0.22 | -2.6% | $8.22 | $8.35 | $7.94 | 20,181 | |
| $8.31 | +0.16 | +2.0% | $8.21 | $8.40 | $7.95 | 16,561 | |
| $8.15 | -0.12 | -1.5% | $8.12 | $8.37 | $7.90 | 11,623 | |
| $8.27 | +0.03 | +0.4% | $8.265 | $8.49 | $8.19 | 6,474 | |
| $8.24 | 0.00 | 0.0% | $8.415 | $8.53 | $8.23 | 8,925 | |
| $8.24 | +0.11 | +1.4% | $8.10 | $8.47 | $8.10 | 12,404 | |
| $8.13 | -0.37 | -4.4% | $8.47 | $8.80 | $7.98 | 18,151 | |
| $8.50 | -0.06 | -0.7% | $8.43 | $8.60 | $8.43 | 8,291 | |
| $8.56 | +0.06 | +0.7% | $8.51 | $8.66 | $8.51 | 10,301 | |
| $8.50 | +0.16 | +1.9% | $8.44 | $8.80 | $8.40 | 22,973 | |
| $8.34 | +0.21 | +2.6% | $8.08 | $8.42 | $8.03 | 15,471 | |
| $8.13 | +0.21 | +2.7% | $7.90 | $8.13 | $7.85 | 45,716 | |
| $7.92 | -0.04 | -0.5% | $7.94 | $7.965 | $7.85 | 15,104 | |
| $7.96 | -0.02 | -0.3% | $8.00 | $8.066 | $7.882 | 26,612 | |
| $7.98 | +0.02 | +0.3% | $7.96 | $8.065 | $7.92 | 32,313 | |
| $7.96 | -0.06 | -0.7% | $8.02 | $8.05 | $7.92 | 5,398 | |
| $8.02 | -0.03 | -0.4% | $8.02 | $8.13 | $7.96 | 15,610 | |
| $8.05 | +0.13 | +1.6% | $7.90 | $8.085 | $7.90 | 23,233 | |
| $7.92 | -0.08 | -1.0% | $8.02 | $8.09 | $7.91 | 11,582 | |
| $8.00 | +0.05 | +0.6% | $8.03 | $8.10 | $7.90 | 20,019 | |
| $7.95 | -0.08 | -1.0% | $8.00 | $8.19 | $7.95 | 19,221 | |
| $8.03 | +0.06 | +0.8% | $7.97 | $8.185 | $7.97 | 12,122 | |
| $7.97 | -0.03 | -0.4% | $7.99 | $8.09 | $7.95 | 9,077 | |
| $8.00 | -0.09 | -1.1% | $8.07 | $8.075 | $7.96 | 10,910 | |
| $8.09 | +0.06 | +0.7% | $8.00 | $8.10 | $7.96 | 39,265 | |
| $8.03 | -0.12 | -1.5% | $8.18 | $8.18 | $8.015 | 8,346 | |
| $8.15 | +0.20 | +2.5% | $7.95 | $8.15 | $7.868 | 15,710 | |
| $7.95 | 0.00 | 0.0% | $7.94 | $8.043 | $7.91 | 9,094 | |
| $7.95 | -0.07 | -0.9% | $7.90 | $8.15 | $7.85 | 12,314 | |
| $8.02 | +0.02 | +0.2% | $8.00 | $8.279 | $7.91 | 9,893 | |
| $8.00 | -0.20 | -2.4% | $8.37 | $8.37 | $7.85 | 24,493 | |
| $8.20 | +0.16 | +2.0% | $8.05 | $8.40 | $7.85 | 36,450 | |
| $8.04 | -0.07 | -0.9% | $8.13 | $8.26 | $8.00 | 21,033 | |
| $8.11 | +0.18 | +2.3% | $7.92 | $8.12 | $7.90 | 32,326 | |
| $7.93 | +0.03 | +0.4% | $8.00 | $8.00 | $7.91 | 20,639 | |
| $7.90 | +0.25 | +3.3% | $7.67 | $7.90 | $7.67 | 26,608 | |
| $7.65 | +0.07 | +0.9% | $7.42 | $7.66 | $7.42 | 10,539 | |
| $7.58 | +0.03 | +0.4% | $7.36 | $7.58 | $7.36 | 6,055 | |
| $7.55 | +0.07 | +0.9% | $7.45 | $7.579 | $7.365 | 11,289 | |
| $7.48 | -0.07 | -0.9% | $7.64 | $7.64 | $7.37 | 10,660 | |
| $7.55 | +0.47 | +6.6% | $6.94 | $7.63 | $6.94 | 52,268 |
Splits
1 split · NASDAQ:HBIO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- LS Exchange:A423J5
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- LS Exchange
- Currency
- EUR
What changed lately
Latest news release · Nov 10, 2026
Harvard Bioscience Announces Third Quarter 2026 Financial Results
Latest earnings call · Nov 10, 2026
Harvard Bioscience (NASDAQ:HBIO) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 10, 2026
Q3 2026 Earnings Presentation
Earnings · 15 slides
Latest news
Harvard Bioscience Announces Third Quarter 2026 Financial Results
Nov 10, 2026
Closed $9.26 (+1.9%) on Nov 10, 2026
Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
Nov 4, 2026
Closed $8.61 (-0.7%) on Nov 4, 2026
Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8: 00 AM ET
Oct 27, 2026
Closed $8.35 (+0.4%) on Oct 27, 2026
Harvard Bioscience Announces Creation of Scientific Advisory Board
Oct 6, 2026
Closed $8.50 (-0.7%) on Oct 7, 2026
Harvard Bioscience Announces Second Quarter 2026 Financial Results
Aug 11, 2026
Closed $6.13 (-4.1%) on Aug 11, 2026
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8: 00 AM ET
Jul 28, 2026
Closed $5.92 (-1.2%) on Jul 28, 2026
Harvard Bioscience Announces First Quarter 2026 Financial Results
May 12, 2026
Closed $5.41 (-20.9%) on May 12, 2026
Harvard Bioscience to Participate in Upcoming Investor Conferences
May 7, 2026
Closed $6.79 (-6.2%) on May 7, 2026
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8: 00 AM ET
Apr 28, 2026
Closed $6.45 (-5.6%) on Apr 28, 2026
Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results
Mar 12, 2026
Closed $4.94 (-2.6%) on Mar 12, 2026
Harvard Bioscience, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 16 in the last 12 months · 102 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest Nov 10, 2026
- Decks
- 44 decks · latest Nov 10, 2026
Where Harvard Bioscience, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:HBIO · Home listing | NASDAQ | United States | USD |
| BOATS:HBIO | BOATS | United States | USD |
| Frankfurt:HBI0 | Frankfurt | Germany | EUR |
| gettex:HBI0 | gettex | Germany | EUR |
| Lang & Schwarz:A423J5 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A423J5 · This page | LS Exchange | Germany | EUR |
| Munich:HBI0 | Munich | Germany | EUR |
Valuation
EV/sales 0.8× against a median of 1.2×: 5th lowest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $71.90M USD
- P/E
- Loss
- EV/sales
- 0.8×
- EV/EBITDA
- 28.4×
- Price/book
- 7.8×
- Gross margin
- 57.4%
- Operating margin
- −1.8%
- Net margin
- −13.2%
- Debt to equity
- 7.3×
- Beta vs S&P 500
- 1.34
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Harvard Bioscience, Inc. · NASDAQ:HBIO | US$39.60M | US$71.90M | n/a | 0.8× | 28.4× | 7.8× | −13.2% | 7.3× | 1.34 |
| Labiana Health SA · BME:LAB | US$44.34M | US$70.55M | 15.7× | 0.9× | 5.8× | 8.0× | 3.4% | 5.9× | n/a |
| Access Bio, Inc. · KRX:950130 | US$44.15M | −US$191.0M | n/a | −10.8× | n/a | 0.1× | −468.1% | 0.0× | n/a |
| EDX Medical Group plc · LSE:EDX | US$43.75M | US$39.93M | n/a | 92.3× | n/a | 15.4× | n/a | 0.0× | n/a |
| Osang Healthcare Co. Ltd. · KRX:036220 | US$42.35M | US$24.18M | n/a | 0.3× | n/a | 0.2× | −8.8% | 0.1× | n/a |
| ABL Diagnostics SA · EURONEXT:ABLD | US$41.26M | US$42.31M | 38.1× | 5.5× | 42.8× | 5.3× | 14.2% | 0.3× | n/a |
| hVIVO plc · LSE:HVO | US$40.99M | US$42.21M | n/a | 0.7× | 7.5× | 1.0× | −12.8% | 0.4× | n/a |
| CytoGen, Inc. · KRX:217330 | US$38.59M | US$31.67M | n/a | 1.6× | n/a | 1.6× | −38.5% | 0.4× | n/a |
| HUMASIS Co., Ltd. · KRX:205470 | US$37.49M | −US$89.15M | n/a | −3.8× | n/a | 0.2× | −49.2% | 0.0× | n/a |
| IXICO PLC · LSE:IXI | US$37.25M | US$35.79M | n/a | 4.2× | n/a | 2.7× | −25.3% | 0.1× | n/a |
| Mabion SA · GPW:MAB | US$35.40M | US$41.96M | n/a | 9.7× | n/a | 6.0× | −321.4% | 1.3× | n/a |
| Median of the others | US$41.12M | US$37.86M | 26.9× | 1.2× | 7.5× | 2.1× | −25.3% | 0.2× |
Forecasts
1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 13.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.34 · 2 analysts
- Revenue, year to Dec 2026
- 90.09M · 3 analysts
Team and board
| Officer | Role |
|---|---|
| John Duke | President & Chief Executive Officer |
| Mark Frost | Chief Financial Officer and Treasurer |
| David Panzarella | Senior Vice President, Commercial |
| Diane Houston | Vice President, Global IT |
| Lori Packer | Vice President, Global People Operations |
| Nitya Shetty | Vice President, Global Research and Development |
Events
Calls
| Call | When | Status |
|---|---|---|
| Harvard Bioscience (NASDAQ:HBIO) Q3 2026 Earnings Call | Tue, Nov 10, 2026 · 8:00 AM ET | Replay |
| Harvard Bioscience (NASDAQ:HBIO) Q2 2026 Earnings Call | Tue, Aug 11, 2026 · 8:00 AM ET | Replay |
| Harvard Bioscience (NASDAQ:HBIO) Q1 2026 Earnings Call | Tue, May 12, 2026 · 8:00 AM ET | Replay |
| Harvard Bioscience (NASDAQ:HBIO) Q4 2025 Earnings Call | Thu, Mar 12, 2026 · 8:00 AM ET | Replay |
| Harvard Bioscience (NASDAQ:HBIO) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 8:00 AM ET | Replay |
| Harvard Bioscience (NASDAQ:HBIO) Q2 2025 Earnings Call | Mon, Aug 11, 2025 · 8:00 AM ET | Replay |
| Harvard Bioscience (NASDAQ:HBIO) Q1 2025 Earnings Call | Mon, May 12, 2025 · 8:00 AM ET | Replay |
| Harvard Bioscience (NASDAQ:HBIO) Q4 2024 Earnings Call | Wed, Mar 12, 2025 · 8:00 AM ET | Replay |
| Harvard Bioscience (NASDAQ:HBIO) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 8:00 AM ET | Replay |
| Harvard Bioscience (NASDAQ:HBIO) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 10:00 AM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | +1.9% |
| Q2 2026 | Aug 11, 2026 · Before open | −4.1% |
| Q1 2026 | May 12, 2026 · Before open | −20.9% |
| Q4 2025 | Mar 5, 2026 | −4.1% |
| Q3 2025 | Nov 6, 2025 · Before open | −7.3% |
| Q2 2025 | Aug 11, 2025 · Before open | −9.3% |
| Q1 2025 | May 12, 2025 · Before open | +11.8% |
| Q4 2024 | Mar 12, 2025 | −16.0% |
| Q3 2024 | Nov 7, 2024 · Before open | −15.3% |
| Q2 2024 | Aug 8, 2024 · Before open | +11.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · Before open | −4.3% |
| Q4 2023 | Mar 7, 2024 · Before open | +9.7% |
| Q3 2023 | Nov 7, 2023 · Before open | −1.2% |
| Q2 2023 | Aug 8, 2023 · Before open | −2.0% |
| Q1 2023 | Apr 25, 2023 · Before open | +7.1% |
| Q4 2022 | Mar 9, 2023 · Before open | +7.3% |
| Q3 2022 | Nov 8, 2022 · After close | −9.5% |
| Q2 2022 | Aug 3, 2022 · After close | −5.5% |
| Q1 2022 | May 4, 2022 · Before open | −18.1% |
| Q4 2021 | Mar 8, 2022 · Before open | +7.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 15 slides | Nov 10, 2026 |
| Investor Presentation (November 2026) | Investor deck | 32 slides | Nov 10, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 15 slides | Aug 11, 2026 |
| Investor Presentation (August 2026) | Investor deck | 32 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 31 slides | May 12, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 13 slides | May 12, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 14 slides | Mar 12, 2026 |
| Investor Presentation (March 2026) | Investor deck | 30 slides | March 2026 |
| Investor Presentation (January 2026) | Investor deck | 15 slides | January 2026 |
| Q3 2025 Earnings Presentation | Earnings | 11 slides | Nov 6, 2025 |
All 44 decks
Financings
| Raise | Date |
|---|---|
| Senior secured term loans, including a convertible term loan, with warrants Closed: US$40M raised · Warrants at US$0.5 · Guggenheim Securities Dealers: Guggenheim Securities Buyers: BroadOak Capital Partners ($40 million credit facility of three term loans, plus warrants for 2 million shares) Use of proceeds: Retire existing debt obligations and associated fees, and strengthen balance sheet and capital structure | Dec 17, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 86.5M | 94.1M | 112.3M | 113.3M | 118.9M | 102.1M | 116.2M | 120.8M | 77.4M | 104.5M |
| Cost of revenue | 36.6M | 39.4M | 46.2M | 52.5M | 51.3M | 44.1M | 51.9M | 57.6M | 38.2M | 56.1M |
| Gross profit | 49.9M | 54.8M | 66.1M | 60.8M | 67.7M | 58.0M | 64.3M | 63.2M | 39.2M | 48.4M |
| Research and development | 8.82M | 10.4M | 11.8M | 12.3M | 10.8M | 8.69M | 10.7M | 11.0M | 5.64M | 5.39M |
| Selling, general and administrative | 17.7M | 21.5M | 22.8M | 24.5M | 24.3M | 23.5M | 22.8M | 21.4M | 18.6M | 20.9M |
| Operating income | -48.6M | -6.21M | 1.89M | -6.93M | 2.07M | 221.0K | 377.0K | 984.0K | -635.0K | -3.00M |
| Depreciation and amortization | 1.74M | 1.73M | 1.47M | 1.45M | 1.78M | 1.92M | 1.99M | 2.42M | 1.32M | 1.53M |
| EBITDA | -46.8M | -4.48M | 3.37M | -5.48M | 3.85M | 2.14M | 2.36M | 3.41M | 682.0K | -1.47M |
| Interest expense | 1.30M | 800.0K | 3.59M | 2.55M | 1.54M | 4.83M | 5.41M | 5.37M | 713.0K | 639.0K |
| Income before tax | -57.4M | -11.7M | -2.56M | -9.18M | -140.0K | -7.29M | -5.50M | -7.97M | -2.62M | -3.08M |
| Income tax | -686.0K | 740.0K | 859.0K | 337.0K | 148.0K | 518.0K | -815.0K | -3.68M | -605.0K | 1.23M |
| Net income | -56.7M | -12.4M | -3.42M | -9.52M | -288.0K | -7.81M | -4.69M | -2.92M | -865.0K | -4.31M |
| Earnings per share, basic | -1.28 | -0.28 | -0.08 | -0.23 | -0.01 | -0.20 | -0.12 | -0.08 | -0.02 | -0.13 |
| Earnings per share, diluted | -1.28 | -0.28 | -0.08 | -0.23 | -0.01 | -0.20 | -0.12 | -0.08 | -0.02 | -0.13 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 8.61M | 4.11M | 4.28M | 4.51M | 7.82M | 8.32M | 8.34M | 8.17M | 5.73M | 5.60M |
| Short-term investments | 0 | 0 | ||||||||
| Receivables | 16.0M | 14.9M | 16.1M | 16.7M | 21.8M | 17.8M | 20.7M | 21.5M | 13.4M | 15.7M |
| Inventory | 20.8M | 23.2M | 24.7M | 26.4M | 27.6M | 22.3M | 22.1M | 25.1M | 16.8M | 20.0M |
| Current assets | 48.2M | 45.1M | 49.0M | 51.1M | 61.6M | 51.7M | 53.6M | 57.8M | 47.5M | 45.5M |
| Property, plant and equipment | 4.79M | 5.11M | 3.98M | 3.37M | 3.42M | 3.96M | 4.78M | 5.90M | 3.74M | 4.30M |
| Goodwill | 9.56M | 56.3M | 57.1M | 56.3M | 57.7M | 58.6M | 57.4M | 57.3M | 36.3M | 38.0M |
| Total assets | 80.1M | 126.6M | 137.4M | 145.4M | 162.3M | 156.3M | 164.9M | 168.6M | 109.4M | 107.8M |
| Accounts payable | 3.65M | 4.79M | 5.55M | 6.45M | 4.91M | 5.97M | 5.34M | 7.36M | 4.41M | 6.20M |
| Current liabilities | 22.0M | 55.0M | 26.5M | 23.2M | 25.3M | 21.1M | 25.3M | 25.5M | 14.0M | 14.6M |
| Long-term debt | 35.9M | 0 | 30.7M | 43.0M | 45.1M | 46.3M | 46.9M | 54.8M | 8.98M | 11.4M |
| Total debt | 35.9M | 37.0M | 37.0M | 46.8M | 48.3M | 48.0M | 53.8M | 60.8M | 11.9M | 13.8M |
| Total liabilities | 66.3M | 63.3M | 64.3M | 73.1M | 78.9M | 79.6M | 83.2M | 85.9M | 28.5M | 35.6M |
| Shareholders' equity | 13.7M | 63.3M | 73.1M | 72.2M | 83.4M | 76.7M | 81.7M | 82.7M | 80.9M | 72.2M |
| Shares outstanding | 4.47M | 44.1M | 43.4M | 42.1M | 41.1M | 39.4M | 38.2M | 37.4M | 35.0M | 35.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 6.73M | 1.44M | 14.0M | 1.15M | 1.26M | 9.33M | 8.04M | 2.88M | 1.06M | 5.38M |
| Capital spending | -1.26M | -2.64M | -1.79M | -1.59M | -1.20M | -1.15M | -1.22M | -986.0K | -890.0K | -1.48M |
| Free cash flow | 5.47M | -1.20M | 12.2M | -438.0K | 67.0K | 8.18M | 6.83M | 1.90M | 167.0K | 3.90M |
| Cash from investing | -1.86M | -1.34M | -1.80M | -1.59M | -1.34M | -1.40M | -229.0K | -53.8M | -917.0K | -62.0K |
| Cash from financing | -1.29M | -131.0K | -12.1M | -2.84M | -252.0K | -7.97M | -7.62M | 53.1M | -1.79M | -4.87M |
| Dividends paid | -1.63M | -200.0K | -221.0K | 0 | 0 | |||||
| Share buybacks | -577.0K | -2.52M | -1.63M | -3.51M | -1.14M | -221.0K | 4.56M | 160.0K | 182.0K | |
| Change in cash | 4.51M | -175.0K | -225.0K | -3.31M | -496.0K | -18.0K | 162.0K | 2.44M | 137.0K | -1.15M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Current report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 22, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Current report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 10, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 2, 2026 | Management or board change | SEC |
| SD · Specialized disclosure | May 27, 2026 | ESG report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Current report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Mar 23, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 17, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 13, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| 8-K · Current report | Mar 10, 2026 | Management or board change | SEC |
| 8-K · Current report | Mar 6, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 10, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Feb 9, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 5, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 5, 2026 | Other filings | SEC |
| DEF 14A · Proxy statement | Jan 30, 2026 | Meeting notice | SEC |
| S-3 · Registration statement | Jan 30, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 29, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Jan 20, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jan 20, 2026 | Current report | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 17, 2025 | Material contract | SEC |
| 8-K · Current report | Dec 5, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 3, 2025 | Current report | SEC |
| 8-K · Current report | Sep 9, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 13, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 25, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 17, 2025 | Management or board change | SEC |
| 8-K/A · Current report, amended | Jun 27, 2025 | Current report | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| 8-K · Current report | Jun 13, 2025 | Management or board change | SEC |
| 3 · Initial statement of ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 2, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 30, 2025 | Big-stake notice | SEC |
| SD · Specialized disclosure | May 27, 2025 | ESG report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 8, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 22, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 16, 2025 | Management or board change | SEC |
| 8-K · Current report | Apr 10, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 17, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2025 | Results | SEC |
| 8-K · Current report | Mar 11, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 30, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 26, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 12, 2024 | Other filings | SEC |
| S-3 · Registration statement | Dec 6, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| SD · Specialized disclosure | May 29, 2024 | ESG report | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 8-K · Current report | May 14, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 3, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 3, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 3, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 3, 2024 | Material contract | SEC |
| 8-K · Current report | Mar 26, 2024 | Management or board change | SEC |
| SC 13G · Big-stake notice | Mar 19, 2024 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 7, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 7, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 26, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 22, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 5, 2024 | Results | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2023 | Results | SEC |
| SC 13G · Big-stake notice | Aug 28, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 21, 2023 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Aug 16, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 9, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2023 | Results | SEC |
| UPLOAD · Letter from the SEC | Jul 28, 2023 | Other filings | SEC |
| 8-K · Current report | Jun 20, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Jun 13, 2023 | Insider trade | SEC |
| SD · Specialized disclosure | May 30, 2023 | ESG report | SEC |
| 4 · Change in ownership | May 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2023 | Insider trade | SEC |
| 8-K · Current report | May 15, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Apr 26, 2023 | Quarterly report | SEC |
| 8-K · Current report | Apr 25, 2023 | Results | SEC |
| ARS · Annual report to shareholders | Apr 7, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 5, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 15, 2023 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2023 | Current report | SEC |
| 8-K · Current report | Mar 10, 2023 | Management or board change | SEC |
| 10-K · Annual report | Mar 9, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2023 | Results | SEC |
| 4 · Change in ownership | Mar 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 16, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 15, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 19, 2023 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 11, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2023 | Insider trade | SEC |
| 8-K/A · Current report, amended | Jan 3, 2023 | Management or board change | SEC |
| SC 13G · Big-stake notice | Dec 21, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Dec 12, 2022 | Management or board change | SEC |
| 4 · Change in ownership | Dec 2, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 8, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2022 | Results | SEC |
| 4 · Change in ownership | Sep 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 4, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2022 | Results | SEC |
| 4 · Change in ownership | Jul 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2022 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jul 8, 2022 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jun 21, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2022 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Harvard Bioscience, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 4,573,080
- Fully diluted
- 4,573,080
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 4,573,080 | Nov 3, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.50 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 4,573,080 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Gagnon Other companies: Purple Biotech Ltd. (Board Member · Since at least Mar 18, 2026); Opus Genetics, Inc. (Chief Financial Officer · Since at least Sep 2, 2025); Bone Biologics Corp (Director · Since at least Jan 8, 2024); Verastem, Inc. (Director · Since at least Aug 28, 2018); Clean Harbors, Inc. (EVP CFO and Treasurer · Aug 20, 2012 – Sep 11, 2012 · Past); Biogen Inc. (Vice President, Finance · Nov 3, 2010 – Feb 28, 2012 · Past) | Director · Since at least Nov 18, 2013 |
| Bertrand Loy Other companies: ITT Inc. (Director · Since at least Jun 29, 2026); Ashland Inc. (Director · Since at least May 15, 2026); Entegris, Inc. (Executive Chair, Director · Since at least Dec 1, 2010); BTU International Inc (Director · Jun 7, 2010 – Jan 30, 2015 · Past) | Director · Nov 6, 2014 – May 21, 2024 · Past |
| Earl R. Lewis Other companies: Tecogen Inc. (Director · Since at least Jul 7, 2014); American DG Energy Inc (Director · Sep 2, 2010 – Sep 2, 2010 · Past); NxStage Medical Inc (Director · Oct 27, 2008 – Feb 21, 2019 · Past); FLIR Systems Inc. (Director · Dec 31, 2005 – May 14, 2021 · Past) | Director · May 25, 2006 – Jan 2, 2018 · Past |
| Mark Frost Other companies: Fathom Digital Manufacturing Corp (Chief Financial Officer, Director · Feb 25, 2022 – Apr 4, 2024 · Past); Analogic Corporation (SVP, CFO & Treasurer · Nov 30, 2015 – Dec 5, 2016 · Past); AngioDynamics, Inc. (EVP and CFO · Nov 30, 2012 – Aug 6, 2015 · Past); Albany Molecular Research Inc (Chief Financial Officer · May 5, 2006 – Sep 14, 2012 · Past) | Chief Financial Officer and Treasurer · Since at least May 12, 2025 |
| Alan Edrick Other companies: OSI Systems, Inc. (Executive Vice President and Chief Financial Officer · Since at least Jul 25, 2006) | Director · Sep 3, 2019 – May 21, 2024 · Past |
| David Green Other companies: Harvard Apparatus Regenerative Technology Inc (Director · Since at least Oct 16, 2013) | Director · Mar 22, 2006 – Feb 7, 2017 · Past |
| James W Green Other companies: OSI Systems, Inc. (Pres., Spacelabs Healthcare · Jul 5, 2019 – Jul 5, 2019 · Past) | Director · Since at least May 23, 2019 |
| John F Kennedy Other companies: Harvard Apparatus Regenerative Technology Inc (Director · Oct 16, 2013 – Mar 14, 2017 · Past) | Director · May 25, 2006 – Mar 23, 2021 · Past |
| Kamalam Unninayar Other companies: Tetraphase Pharmaceuticals Inc (Chief Financial Officer · Oct 16, 2017 – Jan 17, 2018 · Past) | Chief Financial Officer · Nov 26, 2018 – Mar 7, 2019 · Past |
| Katherine A Eade Other companies: Vaxxinity, Inc. (Director · Feb 1, 2023 – Jun 20, 2023 · Past) | Director · Since at least Oct 24, 2017 |
All 32 people
| Person | Seat |
|---|---|
| Michael A Rossi Other companies: LENSAR, Inc. (Interim CFO · Since at least May 29, 2026) | Chief Financial Officer · Jul 18, 2019 – Dec 29, 2022 · Past |
| Susan M Steele Other companies: Hill International Inc (Director · Jun 11, 2019 – Dec 27, 2022 · Past) | Director · Apr 6, 2020 – Jan 4, 2021 · Past |
| William Snider Other companies: Telesis Bio, Inc. (Director · Jun 5, 2023 – Jun 5, 2023 · Past) | Director · Since at least Dec 17, 2025 |
| Bryce Anthony Chicoyne | Chief Financial Officer · Aug 9, 2006 – May 1, 2007 · Past |
| Chane Graziano | Chief Executive Officer, Director · Aug 9, 2006 – Dec 11, 2012 · Past |
| David Panzarella | Senior Vice President, Commercial · Since at least Nov 5, 2026 |
| Diane Houston | Vice President, Global IT · Since at least Nov 5, 2026 |
| George Uveges | Director · Mar 17, 2006 – Mar 7, 2018 · Past |
| Jeffrey Duchemin | Chief Executive Officer, Director · Aug 26, 2013 – Jul 7, 2019 · Past |
| Jennifer Cote | Chief Financial Officer · Jan 1, 2023 – Mar 19, 2025 · Past |
| John Duke | Chief Executive Officer, Director · Since at least Jun 2, 2025 |
| Kenneth Fletcher Olson | Chief Operating Officer · Nov 1, 2020 – Dec 29, 2021 · Past |
| Lori Packer | Vice President, Global People Operations · Since at least Nov 5, 2026 |
| Neal J Harte | Director · May 25, 2006 – May 25, 2016 · Past |
| Nitya Shetty | Vice President, Global Research and Development · Since at least Nov 5, 2026 |
| Robert A Dishman | Director · Jun 4, 2012 – Apr 28, 2015 · Past |
| Seth Benjamin Benson | Director · Since at least Jul 16, 2025 |
| Stephen J Denelsky | Director · Since at least Sep 5, 2025 |
| Susan M Luscinski | Chief Operating Officer · Aug 9, 2006 – Nov 1, 2013 · Past |
| Thomas W Loewald | Director · Oct 24, 2017 – May 21, 2024 · Past |
| Yoav Sibony | VP - Global Sales · Oct 21, 2013 – Aug 3, 2015 · Past |
| Yong Sun | VP - Commercial Operations · Oct 28, 2013 – Jan 1, 2019 · Past |
Log in to ask 6ix AI your own questions about Harvard Bioscience, Inc.